Wave Life Sciences is trading 7.3% higher at $3.97 now after GSK selected a Wave-developed candidate for a liver-disease indication, triggering a $12 million milestone payment. - The candidate will move into GSK’s development pipeline. - Wave remains eligible for additional milestones and tiered royalties. - Shares closed at $3.70 on September 30; trading volume data was not provided.